The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...

Discover why Edgewise Therapeutics, Inc. is rated Buy amid strong trial data, unique HCM treatment, and major 2026 catalysts. Click for this EWTX update.

FDA approved CYTK's Myqorzo for oHCM. It reduces heart's pumping ability, has a warning for heart failure and expected to ...

Blood pressure may rise with age, usually due to narrowing or stiffening of arteries, but certain factors could also cause low blood pressure. Some blood pressure elevation may be unavoidable for some ...